A new cancer drug, known as BLU-667, has shown promise in human clinical trials

A new cancer drug known as BLU-667 has moved through phase I human trials, and the results are promising. Taken orally, the drug targets what are known as RET-driven cancers, including types of thyroid and lung cancers, which are normally hard to treat.

Continue Reading Promising cancer drug aces human clinical trials

Category: Medical


Related Articles: